scholarly journals A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, 10 March 2006

Biologicals ◽  
2007 ◽  
Vol 35 (4) ◽  
pp. 367-371 ◽  
Author(s):  
Geetha P. Bansal
Keyword(s):  
Monoclonal Antibodies ◽  
Infectious Diseases ◽  
Passive Immunization ◽  
Hiv Aids

scholarly journals Definition of a novel vaccination pathway in PLWHA: experience of a Southern University Hospital

2020 ◽  
Vol 30 (Supplement_5) ◽  
Author(s):  
S D'Amato ◽  
G F Pellicanò ◽  
C Genovese ◽  
F Mazzitelli ◽  
G Nunnari ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Vaccination Coverage ◽  
Clinical Pathway ◽  
Drop Out ◽  
University Hospital ◽  
Treatment Center ◽  
People Living With Hiv ◽  
Vaccination Rates ◽  
Operating Unit ◽  
Hiv Aids

Abstract Background At the end of 2018 across the globe there are ∼37.9 million people with HIV/AIDS also thanks to the use of HAART which led to an increase in life expectancy. The Italy Immunization Plan 2017-19 recommend vaccines to these patients but a protocol still isn't present. Moreover, despite the availability of effective vaccines, coverage remained very low for many reasons including problems with privacy. The objectives of this study were a) the appliance of a shared clinical pathway between the “Immunization Center of Hospital Hygiene Operating Unit” and the “HIV/AIDS Disease Prevention, Diagnosis and Treatment Center of Infectious Diseases Operating Unit” b) the increase in vaccination coverage and the evaluation of side effects. Methods A prospective study was conducted from Oct 2019 to Feb 2020 at the G. Martino University Hospital of Messina. In particular, of the 138 patients followed by the Infectious Diseases OU, after evaluation of their immune status, 62% were enrolled in this study. Following the acquisition of informed consent, we collected socio-anagraphical data and we started the free administration of vaccines by providing an hoc calendar in the Immunization Center. Statistical analysis was performed with R software. Results The sample was represented by 86 patients (74% males and 26% females, 21% foreigners and 79% Italian, mean age=40±13.6 SD). We didn't observe drop out and no differences were observed for local/systemic AEs generally reported. We obtained an increase of vaccination coverage with a total of 74 doses administered for flu (+164%) and 240 for other vaccines (+172%). In particular, we immunized a total of 74% of patients for HPV (2% in 2018), 42% for HAV (28% in 2018), 37% for HBV (28% in 2018), 58% for pneumococcal (21% in 2018), 54% for meningococcal ACWY and B (0% in 2018). Conclusions The undertook clinical pathway showed the relevance of specific management of these patients and the need to increase the vaccination offer. Key messages The immunization in people living with HIV is priority to reduce the risk of infectious disease. It’s important to implement a shared clinical pathway to increase vaccination rates of these patients. The application of the protocol had an high impact in patients' adhesion to vaccination also thanks to the chance of accessing to the service in a comfortable setting and suitable to protect privacy.

scholarly journals Characterization and protective activity of monoclonal antibodies directed against Fe (3+) ABC transporter substrate-binding protein of Glaesserella parasuis

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Kexin Zhu ◽  
Dong Yu ◽  
Jiahui An ◽  
Yufeng Li
Keyword(s):  
Monoclonal Antibodies ◽  
Abc Transporter ◽  
Subunit Vaccine ◽  
Binding Protein ◽  
Substrate Binding ◽  
Passive Immunization ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
And Control ◽  
Substrate Binding Protein

AbstractGlässer’s disease is caused by the agent Glaesserella parasuis and is difficult to prevent and control. Candidate screening for subunit vaccines contributes to the prevention of this disease. Therefore, in this study, the inactivated G. parasuis reference serovar 5 strain (G. parasuis-5) was used to generate specific monoclonal antibodies (mAbs) to screen subunit vaccine candidates. Six mAbs (1A12, 3E3, 4C6, 2D1, 3E6, and 4B2) were screened, and they all reacted with the G. parasuis serovar 5 strain according to laser confocal microscopy and flow cytometry (FCM). Indirect enzyme-linked immunosorbent assay (ELISA) showed that one mAb 2D1, can react with all 15 reference serovars of G. parasuis. Protein mass spectrometry and Western blot analysis demonstrated that mAb 2D1 specifically reacts with Fe (3+) ABC transporter substrate-binding protein. A complement killing assay found that the colony numbers of bacteria were significantly reduced in the G. parasuis-5 group incubated with mAb 2D1 (p < 0.01) in comparison with the control group. Opsonophagocytic assays demonstrated that mAb 2D1 significantly enhanced the phagocytosis of 3D4/21 cells by G. parasuis (p < 0.05). RAW264.7 cells with stronger phagocytic ability were also used for the opsonophagocytic assay, and the difference was highly significant (p < 0.01). Passive immunization of mice revealed that mAb 2D1 can eliminate the bacteria in the blood and provide protection against G. parasuis-5. Our study found one mAb that can be used to prevent and control G. parasuis infection in vivo and in vitro, which may suggest that Fe (3+) ABC transporter substrate-binding protein is an immunodominant antigen and a promising candidate for subunit vaccine development.

Antisera, Toxoids, Vaccines and Tuberculins in Prophylaxis and Treatment

PEDIATRICS ◽  
1959 ◽  
Vol 23 (2) ◽  
pp. 430-430
Author(s):  
C. ARDEN MILLER
Keyword(s):  
Infectious Diseases ◽  
Passive Immunization ◽  
Active Immunization ◽  
Biological Products

This book begins: "Biological products used in infectious diseases may be divided into three groups, namely: 1) Sera of various types for prophylaxis and treatment by passive immunization; 2) Prophylactics, such as toxins, toxoids, and vaccines (both bacterial and viral), for active immunization; 3) Diagnostic products, such as diluted toxins and tuberculins, used by the clinician to detect the presence or absence of immunity and also of allergy. Most of these materials come within the scope of this book.

Monoclonal Antibodies for Diagnosis of Infectious Diseases in Humans

2019 ◽  
pp. 57-72
Author(s):  
Robert C. Nowinski ◽  
Milton R. Tam ◽  
Lynn C. Goldstein ◽  
Linda Stong ◽  
Cho-Chou Kuo ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Infectious Diseases

scholarly journals Characterization and Protective Activity of Monoclonal Antibodies Directed against Streptococcus suis Serotype 2 Capsular Polysaccharide Obtained Using a Glycoconjugate

Pathogens ◽  
2019 ◽  
Vol 8 (3) ◽  
pp. 139 ◽  
Author(s):  
Guillaume Goyette-Desjardins ◽  
Sonia Lacouture ◽  
Jean-Philippe Auger ◽  
René Roy ◽  
Marcelo Gottschalk ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Capsular Polysaccharide ◽  
Passive Immunization ◽  
Streptococcus Suis ◽  
Diagnostic Tools ◽  
Protective Activity ◽  
Lethal Challenge ◽  
Swine Pathogen ◽  
Suis Serotype ◽  
Streptococcus Suis Serotype 2

Streptococcus suis serotype 2 is an encapsulated bacterium and an important swine pathogen. Opsonizing antibody responses targeting capsular polysaccharides (CPSs) are protective against extracellular pathogens. To elucidate the protective activity of monoclonal antibodies (mAbs) directed against S. suis serotype 2 CPS, mice were immunized with a serotype 2 CPS-glycoconjugate and three hybridomas were isolated; of which, two were murine IgMs and the other a murine IgG1. Whereas the IgMs (mAbs 9E7 and 13C8) showed different reactivity levels with S. suis serotypes 1, 1/2, 2 and 14, the IgG1 (mAb 16H11) was shown to be serotype 2-specific. All mAbs targeted the sialylated chain of the CPSs. Using an opsonophagocytosis assay, the IgMs were opsonizing towards the S. suis serotypes to which they cross-react, while the IgG1 failed to induce bacterial elimination. In a model of mouse passive immunization followed by a lethal challenge with S. suis serotype 2, the IgG1 and IgM cross-reacting only with serotype 14 (mAb 13C8) failed to protect, while the IgM cross-reacting with serotypes 1, 1/2, and 14 (mAb 9E7) was shown to be protective by limiting bacteremia. These new mAbs show promise as new S. suis diagnostic tools, as well as potential for therapeutic applications.

Sign in / Sign up

Export Citation Format

Share Document